New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
21:05 EDTGNOM, ILMNIllumina confirms failed bid for Complete Genomics
Illumina (ILMN) confirmed in a regulatory filing that it is “Party H” as named in the Schedule 14D-9 filed by Complete Genomics (GNOM) in connection with the tender offer by Beta Acquisition Corporation, a wholly owned subsidiary of BGI-Shenzhen, to purchase all of the outstanding common stock of Complete Genomics. Illumina further confirmed that it submitted proposals to acquire Complete Genomics. Illumina’s most recent proposal, submitted on November 5, included the following terms: a per share cash purchase price of $3.30, which represented approximately a 5% premium over the consideration offered by BGI; financed with cash-on-hand; and without any condition for further due diligence. Complete Genomics called Illumina's offer inadequate.
News For ILMN;GNOM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
08:49 EDTILMNIllumina price target lowered to $220 from $300 at Cowen
Subscribe for More Information
October 1, 2015
10:00 EDTILMNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AGCO (AGCO) downgraded to Sell from Neutral at UBS... Banco Santander (SAN) downgraded to Neutral from Overweight at JPMorgan... Crocs (CROX) downgraded to Neutral from Overweight at Piper Jaffray... EZchip (EZCH) downgraded to Hold from Buy at Brean Capital... Illumina (ILMN) downgraded to Market Perform from Outperform at Leerink... ServisFirst (SFBS) downgraded to Hold from Buy at Sandler O'Neill.
06:59 EDTILMNIllumina downgraded to Market Perform from Outperform at Leerink
Leerink analyst Daniel Leonard downgraded Illumina to Market Perform citing a less compelling risk/reward over the next 12 months amid uncertainty regarding the next driver of growth in research. The analyst cut his price target for shares to $185 from $225.
September 30, 2015
20:04 EDTILMNAmoy, Illumina enter into strategic collaboration
Amoy Diagnostics and Illumina (ILMN) announced a strategic collaboration to accelerate the adoption of precision medicine and targeted therapies in China. Under the collaboration, Amoy will develop and commercialize a series of oncology-related tests based on Illumina's next-generation sequencing platforms, including the recently released research use only TruSight Tumor 15 as transferred from Illumina to Amoy. The collaboration reflects the commitment of both companies to provide integrated solutions to meet clinical needs in China.
September 29, 2015
14:40 EDTILMNIllumina volatility increase on wide share price movement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use